Sarepta Therapeutics Cash Flow Statement
SRPT / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Sarepta Therapeutics used $205M in operating cash flow and negative free cash flow of $307M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$713.4M | $235.2M | -$536.0M | -$554.1M | -$418.8M | -$361.9M | -$50.7M | -$361.9M | -$50.7M | -$267.3M | -$220.0M | -$135.8M | -$112.0M | -$121.3M | -$2.3M |
| Depreciation & Amortization | $44.5M | $37.7M | $44.4M | $26.9M | $38.0M | $12.2M | $8.1M | $12.2M | $8.1M | $5.6M | $5.2M | $3.7M | $1.3M | $1.5M | $1.3M |
| Operating Cash Flow | -$205.5M | -$205.8M | -$501.0M | $107.5M | -$443.2M | -$388.7M | -$232.0M | -$388.7M | -$232.0M | -$245.8M | -$149.5M | -$128.5M | -$64.7M | -$29.7M | -$23.7M |
| Capital Expenditures | $102.0M | $137.0M | $76.1M | $82.2M | $38.5M | $61.2M | $12.0M | $61.2M | $12.0M | $5.3M | $3.4M | $25.4M | $2.4M | $108.0K | $1.2M |
| Free Cash Flow | -$307.5M | -$342.7M | -$577.1M | $25.3M | -$481.7M | -$449.8M | -$244.0M | -$449.8M | -$244.0M | -$251.2M | -$152.9M | -$154.0M | -$67.1M | -$29.8M | -$24.9M |
| Share Buybacks | $25.0M | $0 | $0 | - | - | - | - | - | - | - | - | - | - | - | $289.0K |
| FCF Margin | -14.0% | -18.0% | -46.4% | 4.7% | -68.6% | -149.4% | -157.8% | -149.4% | -157.8% | -4633.1% | - | - | - | - | - |